Ocular Therapeutix Inc. (NASDAQ:OCUL) fell 3.1% on Monday . The stock traded as low as $4.65 and last traded at $5.01, with a volume of 988,849 shares. The stock had previously closed at $5.17.

Several brokerages recently weighed in on OCUL. Morgan Stanley upped their price target on Ocular Therapeutix from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, April 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $48.00 price target on shares of Ocular Therapeutix in a research note on Sunday, April 10th. Zacks Investment Research cut Ocular Therapeutix from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research note on Monday, June 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.85.

The company has a 50 day moving average price of $5.46 and a 200-day moving average price of $8.35. The company’s market cap is $109.47 million.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.01. The company had revenue of $458 million for the quarter. Equities analysts anticipate that Ocular Therapeutix Inc. will post ($1.86) EPS for the current year.

In other news, CEO Amarpreet Sawhney bought 10,000 shares of the firm’s stock in a transaction on Thursday, June 9th. The stock was purchased at an average price of $6.70 per share, for a total transaction of $67,000.00. Following the transaction, the chief executive officer now owns 573,733 shares in the company, valued at $3,844,011.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.